Komori
Veritas In Silico (130A) · InitiativeAdvanced

Expansion of the in-house pipeline business targeting nucleic acid drugs and small-molecule drugs

First written in 2026-03-02. 6 of 9 entries say "Advanced", first in 2026-05-11. Latest entry: 2026-10-13.

9entries
1years
9from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst stated2026-03-02 – 2026-05-11Advanced2026-05-11 – 2026-08-03Advanced2026-08-05 – 2026-10-132026: 92026
Same theme, other companies

This thread is not in a theme yet. When the same subject shows up in other companies' filings, you can compare them here.

Full recordFilings, disclosures and news, newest first
Moved together

"Ongoing Acquisition of New Collaborative Drug Discovery Research Agreements" moved the same way as this thread, in the same document, in 3 of its 9 moves.

333222★123456
  1. ★This thread
  2. 1Ongoing Acquisition of New Collaborative Drug Discovery Research Agreements3×
  3. 2Expansion into ASO, mRNA therapeutics, and ncRNA-targeted therapeutics3×
  4. 3Creation of the Second In-House Pipeline in Fiscal 20263×
  5. 4Cash Flow Management and Funding Risks Associated with R&D Investment2×
  6. 5Perfusio-Based Nucleic Acid Pharmaceutical Delivery, Shorter Development Timelines, and Commercialization2×
  7. 6Securing and Developing Specialized Personnel2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Veritas In Silico yet. It last moved in the Share Issuance and Disposal of 2026-10-13: "Advanced".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.